Cargando…

Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial

BACKGROUND: Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus that has a considerable impact on quality of life, but there are few effective therapeutic strategies. The aim of this trial is to determine the efficacy and safety of manual acupuncture (MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Haiping, Shu, Yu, Lv, Peiran, Zhao, Ling, Cheng, Ke, Zhang, Tingting, Song, Yi, Yang, Hua, Tang, Hong, Pei, Jian, Shen, Xueyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586683/
https://www.ncbi.nlm.nih.gov/pubmed/33106185
http://dx.doi.org/10.1186/s13063-020-04811-3
_version_ 1783600049590108160
author Deng, Haiping
Shu, Yu
Lv, Peiran
Zhao, Ling
Cheng, Ke
Zhang, Tingting
Song, Yi
Yang, Hua
Tang, Hong
Pei, Jian
Shen, Xueyong
author_facet Deng, Haiping
Shu, Yu
Lv, Peiran
Zhao, Ling
Cheng, Ke
Zhang, Tingting
Song, Yi
Yang, Hua
Tang, Hong
Pei, Jian
Shen, Xueyong
author_sort Deng, Haiping
collection PubMed
description BACKGROUND: Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus that has a considerable impact on quality of life, but there are few effective therapeutic strategies. The aim of this trial is to determine the efficacy and safety of manual acupuncture (MA) versus sham acupuncture (SA) for DPN. METHODS/DESIGN: This is a study protocol for a randomized, placebo-controlled clinical trial. A total of 118 patients with DPN will be recruited and randomly assigned in a 1:1 ratio to either the MA group or SA group. All patients will receive 24 sessions over 12 weeks. Participants will complete the trial by visiting the research center at month 6 for a follow-up assessment. The primary outcome is peroneal motor nerve conduction velocity (peroneal MNCV) at week 12 compared with baseline. Secondary outcomes include peroneal motor nerve action potential amplitude (peroneal MNAP) and latent period (peroneal MNLP), sural sensory nerve conduction velocity (sural SNCV), action potential amplitude (sural SNAP) and latent period (sural SNLP), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2hPG), glycated hemoglobin (HbAlc) at week 12 compared with baseline, Michigan Neuropathy Screening Instrument (MNSI) score and Diabetes Specific Quality of Life scale (DSQL) at week 12 and month 6 compared with baseline. Safety will be assessed during the whole trial. Masking effectiveness will be assessed by patients. DISCUSSION: This trial may provide high-quality evidence for evaluating the efficacy and safety of MA treatment for DPN compared with SA treatment. Results of this study will be published in peer-reviewed journals. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1800020444. First registered on 29 December 2018, retrospectively registered, http://www.chictr.org.cn/showproj.aspx?Proj=31063.
format Online
Article
Text
id pubmed-7586683
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75866832020-10-27 Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial Deng, Haiping Shu, Yu Lv, Peiran Zhao, Ling Cheng, Ke Zhang, Tingting Song, Yi Yang, Hua Tang, Hong Pei, Jian Shen, Xueyong Trials Study Protocol BACKGROUND: Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus that has a considerable impact on quality of life, but there are few effective therapeutic strategies. The aim of this trial is to determine the efficacy and safety of manual acupuncture (MA) versus sham acupuncture (SA) for DPN. METHODS/DESIGN: This is a study protocol for a randomized, placebo-controlled clinical trial. A total of 118 patients with DPN will be recruited and randomly assigned in a 1:1 ratio to either the MA group or SA group. All patients will receive 24 sessions over 12 weeks. Participants will complete the trial by visiting the research center at month 6 for a follow-up assessment. The primary outcome is peroneal motor nerve conduction velocity (peroneal MNCV) at week 12 compared with baseline. Secondary outcomes include peroneal motor nerve action potential amplitude (peroneal MNAP) and latent period (peroneal MNLP), sural sensory nerve conduction velocity (sural SNCV), action potential amplitude (sural SNAP) and latent period (sural SNLP), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2hPG), glycated hemoglobin (HbAlc) at week 12 compared with baseline, Michigan Neuropathy Screening Instrument (MNSI) score and Diabetes Specific Quality of Life scale (DSQL) at week 12 and month 6 compared with baseline. Safety will be assessed during the whole trial. Masking effectiveness will be assessed by patients. DISCUSSION: This trial may provide high-quality evidence for evaluating the efficacy and safety of MA treatment for DPN compared with SA treatment. Results of this study will be published in peer-reviewed journals. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1800020444. First registered on 29 December 2018, retrospectively registered, http://www.chictr.org.cn/showproj.aspx?Proj=31063. BioMed Central 2020-10-26 /pmc/articles/PMC7586683/ /pubmed/33106185 http://dx.doi.org/10.1186/s13063-020-04811-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Deng, Haiping
Shu, Yu
Lv, Peiran
Zhao, Ling
Cheng, Ke
Zhang, Tingting
Song, Yi
Yang, Hua
Tang, Hong
Pei, Jian
Shen, Xueyong
Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
title Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
title_full Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
title_fullStr Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
title_full_unstemmed Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
title_short Acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
title_sort acupuncture for diabetic peripheral neuropathy: study protocol for a randomized, placebo-controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586683/
https://www.ncbi.nlm.nih.gov/pubmed/33106185
http://dx.doi.org/10.1186/s13063-020-04811-3
work_keys_str_mv AT denghaiping acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT shuyu acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT lvpeiran acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT zhaoling acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT chengke acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT zhangtingting acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT songyi acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT yanghua acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT tanghong acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT peijian acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial
AT shenxueyong acupuncturefordiabeticperipheralneuropathystudyprotocolforarandomizedplacebocontrolledtrial